

Hans Skovgaard Poulsen, MD, DMSc

**Department of Radiation Biology,**

The Finsencenter, Section 6321  
Copenhagen University Hospital,  
Blegdamsvej 9  
DK - 2100 Copenhagen  
Email: hans.skovgaard.poulsen@rh.regionh.dk  
www.radiationbiology.dk  
Phone: (+45) 35 45 63 03 Fax: (+45) 35 45 63 01

---

**Date of Birth:** June 23<sup>rd</sup>. 1949

---

**Current Position:**

Associate Research professor, Chief Physician and Head of Section for Neuro-Oncology and Department of Radiation Biology

---

**Education:**

1978: MD  
1984: DMSc  
1988: Specialist in Oncology

---

**Clinical Responsibilities:**

Neuro-oncology (Head),

Member of the team including GU cancer, sarcoma and tumors in children

---

**Research responsibilities**

*Present research area:* Lung cancer, brain tumors and growth factor receptor studies, with the principal aim to generate more insight into the malignant phenotype, and second aim to extend that knowledge to patient material in terms of testing possible prognostic factors, as well as suggesting new translational treatment modalities; targeting gene therapy alone or in combination with already used modalities.

The laboratory employs 11 people, 1 senior research scientists, 5 Ph.D. students, 1 master student, 2 technicians, 1 research nurse and 1 student worker.

The laboratories have mainly been financed by competitive money from The Danish Medical Research Council, The Danish Cancer Society, University of Copenhagen, Rigshospitalet and several private foundations.

*Supervision experiences:* Mentor (2) and co-mentor (1) for doctoral theses; 17 Ph.D. Studies, 11 Approved, the rest in progress.

In addition several student projects have been supervised.

Referee for a number of international scientific journals.

Initiated and was head of the Receptor Laboratory, The Danish Cancer Society, Aarhus from 1980 to 1989. This laboratory developed new histological methods for oestrogen receptor assays and was one of 3-reference laboratory in Denmark.

Initiated and is head of Department of Radiation Biology, Finsen Centre since 1993.

*Other:*

1990-1994: President, the Danish Association for Cancer Research

1995-1997: Member of the I Scientific Committee of Ethics for Copenhagen and Frederiksberg

1994-2000: Member of the Editorial Board of Lung Cancer  
1998-2006: Member of the Editorial Board of Neuro-Oncology  
1996-2002: Member of the scientific Board, The Danish Cancer Society  
1996-2000: Member of the Board, the European Association of Neuro Oncology  
2000: President, European Association of Neuro Oncology  
1997- 2006: Secretary, the Danish Brain Tumor Study Group (DBTSG)  
1999- 2007: Board member, Patent administration, Biotechnology, University Hospital, Copenhagen  
1999-2002: CSO, Odin Medical A/S  
2000-2007: President, Scandinavian Neuro-Oncology Group (SNOG)  
2003-: Member of the National Board of Patients' Complaints of the Danish Public Health Authorities  
2006-: Board member of Danish Graduate School in Clinical Oncology  
2007-: Member of the scientific Board, The Norwegian Cancer Society  
2009: Visiting Professor at The Preston Robert Tisch Brain Tumor Center at Duke University  
2009-: EU Evaluation Commission, FP7-Health 2010

---

**Teaching experience:**

Associate professor, University of Copenhagen; human biology and oncology

---

**Awards:**

1976: Gold medal for Prize paper in Oncology, University of Aarhus,  
1986: ESTRO travelling award  
1998: Kaj Bunch-Jensen and Allis Bunch-Jensen's award for Cancer Research  
2008: The honouree award of the Danish Society for Cancer Research

---

**Publications:**

140 original articles in scientific journals with peer-review  
9 original articles in journals without peer-review  
7 Book chapters  
3 Patents

## Publikationer (eksklusiv abstracts)

### Resumé

- I. **Poulsen HS:** Prisopgave i radioterapi: Tildelt Aarhus Universitets guldmedalje: Der ønskes en undersøgelse af en in vitro metode til påvisning af humane mammacancer cellers hormonfølsomhed. Undersøgelsen skal baseres på litteraturstudier og egen metodik. Aarhus Universitet 1976, pp 1-103.
- II. **Poulsen HS:** In vitro tests and hormonal treatment of breast cancer. Disputats, Aarhus: Eget forlag 1984, pp 1-89. (Doctoral thesis)

### Original artikler med peer review

1. **Poulsen HS:** Demonstration of hormonal sensitivity in gynaecomastic tissue by thymidine incorporation in vitro. Acta path microbiol scand (section A), 85: 19-24, 1977.
2. Overgaard J, **Poulsen HS:** Brief Communication: Effect of hyperthermia and environmental acidity on the proteolytic activity in murine ascites tumor cells. J Natl Cancer Inst, 58: 1159-1161, 1977.
3. **Poulsen HS:** Absence of association between oestrogen-receptor content and in vitro oestrogen sensitivity in human breast cancer. Acta path microbiol scand (section A), 86: 169-172, 1978.
4. Nielsen HE, **Poulsen HS**, Olsen KJ, Gadeberg CC, Schultz H: Bone mineral content and estrogen receptors in patients with breast cancer. Europ. J. Cancer, 15: 703-707, 1979.
5. **Poulsen HS**, Schultz H, Bichel P: Oestrogen-receptor determinations on fine-needle aspirations from malignant tumours of the breast. Europ J. Cancer, 15: 1431-1438, 1979.
6. Mørch-Jørgensen L, **Poulsen HS**, Larsson L-I: Formaldehyde-Fluorescamine-induced fluorescence of mammary carcinoma cells. Lack of concordance with occurrence of Oestrogen-binding proteins. Virchows Arch B Cell Path, 30; 281-287, 1979.
7. **Poulsen HS**, Schultz HP, Hansen ES: Østrogen receptorbestemmelse på malignt humant mammavæv. Hvorledes undgås falsk negative resultater? Ugeskr. Læg, 143: 192-194, 1981.
8. **Poulsen HS:** Oestrogen Receptor Assay-Limitation of the Method. Europ. J. Cancer 17: 495-501, 1981.
9. **Poulsen HS**, Jensen J, Hermansen C: Human breast cancer: Heterogeneity of estrogen binding sites. Cancer, 48: 1791-1793, 1981.
10. **Poulsen HS**, Frederiksen P: Glucose-6-phosphate dehydrogenase activity in human breast cancer. Lack of association with estrogen receptor content. Acta path. microbiol scand. (section A), 89: 263-270, 1981.
11. **Poulsen HS**, Bichel P, Andersen J: Short-term culture of human breast cancer: In vitro effects of hormones related to patient response. Br J Cancer, 46: 67-74, 1982.

12. Bichel P, **Poulsen HS**, Andersen J: Estrogen receptor content and ploidy of human mammary carcinoma.  
Cancer, 50: 1771 - 1774, 1982.
13. **Poulsen HS**, L. Ozzello L, Andersen J: Oestrogen receptors in human breast cancer. Problems of correlation with histopathological features.  
Virchows Arch ( Pathol Anat ), 397: 103-108, 1982.
14. **Poulsen HS**: Estrogen receptors in human breast cancer. Comparative features of the hydroxylapatite- and Dextran-coated charcoal assay.  
Eur J Cancer Clin Oncol, 18: 1075-1079, 1982.
15. **Poulsen HS**: In vitro tests and hormonal treatment of breast cancer.  
Progress in Surgical Pathology, 1983, pp 37-65.
16. Hermansen C, **Poulsen HS**, Jensen J, Langfeldt JB, Steenskov V, Frederiksen P, Jensen OM: Palpable breast tumours: "Triple diagnosis" and operative strategy, Results of a prospective study.  
Acta Chir Scand, 150: 625-628, 1984.
17. **Poulsen HS**, Bukh A, Rytter L, Thomsen K, Ørntoft T, Andersen HU, Møller NPH, Brünner N: Oestrogen receptor assay. False positive analysis?  
Acta Radiologica Oncology, 23: 109-117, 1984.
18. Jacobsen A, **Poulsen HS**, Madsen EL, Petersen SE, Hansen HS: Ploidy level of human breast carcinoma. Relation to histopathologic features and hormone receptor content  
Acta Radiologica Oncology, 23: 103-107, 1984.
19. Thorpe SM, Olsen K, Pedersen KO, **Poulsen HS**, Rose C: Quality control of estrogen and progesterone receptor analyses in Denmark.  
Res Results Cancer Res, 91: 91-93, 1984.
20. **Poulsen HS**, Ozzello L, King WJ, Greene GL: The use of monoclonal antibodies to estrogen receptors (ER) for immunoperoxidase detection of ER in paraffin sections of human breast cancer tissue.  
J Histochem Cytochem, 33: 87-92, 1985.
21. Ørntoft TF, Mors NPO, Eriksen G, Jacobsen NO, **Poulsen HS**: Comparative immunoperoxidase demonstration of T-antigens in human colorectal carcinomas and morphologically abnormal mucosa.  
Cancer Res, 45: 447-452, 1985.
22. Brünner N, Spang-Thomsen M, **Poulsen HS**, Engelholm SA, Nielsen A, Vindeløv L: Endocrine sensitivity of the receptor-positive T61 human breast carcinoma serially grown in nude mice.  
Int J Cancer, 35: 59-64, 1985.
23. Brünner N, Bastert GB, **Poulsen HS**, Spang-Thomsen M, Engelholm SA, Vindeløv L, Nielsen A, Tommerup N, Elling F: Characterization of the T61 human breast carcinoma established in nude mice.  
Eur J Cancer Clin Oncol, 21: 833-843, 1985.
24. Nielsen HE, Saksø P, **Poulsen HS**, Gadeberg CC: Bone mineral content and estrogen receptors in women with breast tumors.  
Acta Radiologica Oncology, 24: 247-251, 1985.

25. **Poulsen HS**, Hermansen C, Andersen JA, Andersen HU, Jensen J:  
Gynecomasty: Estrogen and androgen receptors. A clinical-pathological investigation.  
*Acta path. microbiol. immunol. scand. (section A)*, 93: 229-233, 1985.
26. Nielsen NSM, **Poulsen HS**: Relation between mammographic findings and  
hormonal receptor content in breast cancer.  
*Am J Roentgenology*, 145: 501-504, 1985.
27. Andersen J, Ørntoft TF, **Poulsen HS**: Semiquantitative oestrogen receptor assay in  
formalin-fixed paraffin sections of human breast cancer tissue using monoclonal  
antibodies.  
*Br J Cancer*, 53: 691-694, 1986.
28. Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, **Poulsen HS**, Andersen AP,  
Loft H, Dombernowsky P, Andersen KW: Combined endocrine treatment of  
postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs.  
tamoxifen plus aminoglutethimide and hydrocortisone.  
*Breast Cancer Res Treat*, 7: 45-50, 1986.
29. Hermansen C, **Poulsen HS**, Jensen J, Langfeldt B, Steenskov V, Frederiksen P,  
Jensen OM: Diagnostic Reliability of Combined Physical Examination, Mammography and  
Fine-Needle Puncture ("Triple Test") in Breast Tumors. A Prospective Study.  
*Cancer*, 60: 1866-1871, 1987.
30. Andersen J, Andersen JA, Ørntoft TF, **Poulsen HS**: Gynecomastia:  
Immunohistochemical demonstration of estrogen receptors.  
*Acta path. microbiol. immunol. scand. (Section A)*, 95: 263-267, 1987.
31. Andersen J, **Poulsen HS**: Immunohistochemical analysis of estrogen receptors (ER)  
using formalin-fixed paraffin-embedded breast cancer tissue: Correlation with clinical endocrine  
response.  
*J. steroid Biochem*, 30: 337-339, 1988.
32. Bentzen SM, **Poulsen HS**, Kaae S, Jensen OM, Johansen H, Mouridsen HT, Daugaard S,  
Arnoldi C: Prognostic factors in osteosarcomas. A regression analysis.  
*Cancer*, 62: 194-202, 1988.
33. Jacobsen A, Hansen V, **Poulsen HS**: DNA profile and steroid receptor content of human  
ovarian cancer.  
*Eur J Gynaec Oncol*, 6: 461-463, 1988.
34. Andersen J, Bentzen SM, **Poulsen HS**: Relationship between radioligand binding assay,  
immunoenzyme assay and immunohistochemical assay for estrogen receptors in  
human breast cancer and association with tumor differentiation.  
*Eur J Cancer Clin Oncol*, 24: 377-384, 1988.
35. Bukh A, Agua MT, Krarup N, **Poulsen HS**, Nordentoft AM, Møller NP:  
A prospective study of circulating immune complexes in patients with breast cancer.  
*Int. J Cancer*, marts 15; 41,364-70, 1988.
36. Thorpe SM, **Poulsen HS**, Pedersen KO, Rose C: Impact of standardization of estrogen and  
progesterone receptor assays of breast cancer biopsies in Denmark.  
*Eur J Cancer Clin Oncol*, 24: 1263-1269, 1988.
37. Andersen J, Ørntoft TF, **Poulsen HS**: Immunohistochemical demonstration of estrogen  
receptors (ER) in formalin-fixed, paraffin-embedded human breast cancer tissue by  
use of a monoclonal antibody to ER<sup>1</sup>.  
*J histochem Cytochem*, 36: 1553-1560, 1988.

38. Andersen J, **Poulsen HS**: Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer.  
Acta Oncologica, 27: 761-765, 1988.
39. Thorpe SM, **Poulsen HS**, Pedersen KO, Rose C: Quality control of receptor analyses of breast cancer tissue in Denmark.  
Acta Oncologica, 27: 621 - 625, 1988.
40. Andersen J, Skovbon H, **Poulsen HS**: Immunocytochemical determination of the estrogen regulated protein M<sub>r</sub> 24.000 in primary breast cancer and response to endocrine therapy.  
Eur J Cancer Clin Oncol, 25: 641-643, 1989.
41. Scopsi L, Balslev E, Brünner N, **Poulsen HS**, Andersen J, Rank F, Larsson L-I: Immunoreactive opioid peptides in human breast cancer.  
American J Pathol, 134, 2: 473-479, 1989.
42. Andersen J, **Poulsen HS**: Immunohistochemical Estrogen Receptor Determination in Paraffin Embedded Tissue. Prediction of response to hormonal treatment in advanced breast cancer.  
Cancer, 64: 1901 - 1908, 1989.
43. Jørgensen LJ, **Poulsen HS**, Nordentoft AM, Jensen OM, Sneppen O: Sarcoma Synoviale.  
Ugeskr Læger, 151: 1325-1328, 1989.
44. Nielsen OS, **Poulsen HS**: Knoglemetastaser.  
Ugeskr Læger, 151: 362-365, 1989.
45. **Poulsen HS**, Nielsen OS, Klee M, Rørth M: Palliative irradiation of Bone Metastases.  
Cancer Treat Review, 16: 41-48, 1989.
46. Rørth M, **Poulsen HS**: Behandling af Kræftsygdomme.  
Ugeskr Læger, 151: 325-330, 1989.
47. Damstrup L, Rørth M, **Poulsen HS**: Growth factors and growth factor receptors in human malignancies, with special reference to human lung cancer: a review.  
Lung Cancer, 5: 49-68, 1989.
48. **Poulsen HS**: Cancer cell cultures and their clinical application.  
Reviews Endocrine-Related Cancer, 33: 17-22, 1989.
49. Krarup-Hansen A, **Poulsen HS**: Extra-visceral soft tissue sarcomas in adults: local treatment, with special reference to irradiation.  
Cancer Treat Reviews, 16: 221-246, 1989.
50. Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB, Thorpe SM, **Poulsen HS**: The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of Steroid-binding assays.  
Eur J Cancer Clin Oncol, 26: 442-449, 1990.
51. Mouridsen HT, Dombernowsky P, Jensen OM, Johansen H, Lund B, Nordentoft A, **Poulsen HS**, Schiødt T, Sneppen O: Sarkom Behandling i Danmark.  
Ugeskr Læger, 152: 989-992, 1990.

52. Andersen J, Thorpe SM, Rose C, Christensen I, Rasmussen BB, **Poulsen HS** : Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. *Acta Oncologica*, 30: 685-690, 1991.
53. Becker U, Andersen J, **Poulsen HS**, Burcharth F, Gluud C, Horn T: Enzyme immunoassay of oestrogen receptors in needle biopsies from human liver. *Liver*, 11: 292-299, 1991.
54. Hippe E, Jønsson V, von der Maase H, Mathiesen JC, **Poulsen HS**: Homoeostatic response criteria for cancer therapy. *Eur J Cancer*, 27: 1715-1716, 1991.
55. Nørgaard P, **Poulsen HS**: Glucocorticoid receptors in human malignancies: A review. *Ann Oncol*, 2: 541-557, 1991.
56. Nielsen NSM, Andersen J, **Poulsen HS**, Mathiessen O: Prediction of hormone responsiveness by mammographic parenchymal pattern in advanced primary breast cancer. *Breast Cancer Res Treat*, 23: 219-222, 1992.
57. Damstrup L, Andersen J, Kufe DW, Hayes DF, **Poulsen HS**: Immunocytochemical determination of the Estrogen-regulated proteins M<sub>r</sub> 24.000, M<sub>r</sub> 52.000 and DF3 breast cancer associated antigen: Clinical value in advanced breast cancer and correlation with estrogen receptor. *Ann Oncol*, 3: 71-77, 1992.
58. Becker U, Andersen J, **Poulsen HS**, Horn T: Variation in hepatic estrogen receptor concentrations in patients with liver disease: A multivariate analysis. *Scand J Gastroenterol*, 27: 355-361, 1992.
59. Damstrup L, Rygaard K, Spang-Thomsen M, **Poulsen HS**: Expression of the Epidermal Growth Factor Receptor in Human Small Cell Lung Cancer Cell Lines. *Cancer Res* 52: 3089- 3093, 1992.
60. Nørgaard P, Damstrup L, Spang-Thomsen M, **Poulsen HS**: Transforming growth factor- b. En potent multifunktionel vækstfaktor for normale og maligne celler. *Ugeskr Læger*, 154: 3494-3498, 1992.
61. Becker U, Andersen J, **Poulsen HS**, Horn T: Hepatic cytosolic oestrogen receptors in patients with liver disease. *J Intern Med*. Feb; 233(2), 165-72, 1993.
62. Damstrup L, Rygaard K, Spang-Thomsen M, **Poulsen HS**: Expression of transforming growth factor  $\beta$  (TGF  $\beta$ ) receptors of TGF  $\beta$  1, TGF  $\beta$  2, and TGF $\beta$  3 in human small cell lung cancer cell lines. *Br J Cancer*, 67: 1015-1021, 1993.
63. Nørgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, **Poulsen HS**: Growth suppression by transforming growth factor b of human small cell lung cancer cell lines is associated with expression of type II receptor. *Br J Cancer*, 69: 802 - 808, 1994.
64. Damstrup L, **Poulsen HS**: Review of the curative role of radiotherapy in the treatment of non - small cell lung cancer. *Lung Cancer*, 11: 153- 178, 1994.
65. Bouchelouche PN, Berild D, Nielsen OH, Elmgreen J, **Poulsen HS** :

Leukotriene B4 receptor levels and intracellular calcium, signalling in polymorpho-nuclear leukocytes from patients with Chron's disease.  
Eur J Gastroent Hepatol, 7: 349 - 356, 1995.

66. Nørgaard P, Hougaard S, Spang-Thomsen M, **Poulsen HS**: Transforming Growth Factor  $\beta$  and Cancer.  
Cancer Treat Reviews, 21: 367 - 403, 1995.
67. **Poulsen HS**, Sørensen JB: Management of patients with Lung Cancer.  
Oncology in Practice, 1995.
68. Nørgaard P, Spang-Thomsen M, **Poulsen HS**: Expression and autoregulation of transforming growth factor b receptor mRNA in small- cell lung cancer cell lines.  
Br J Cancer, 73: 1037 - 1043, 1996.
69. Nørgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, **Poulsen HS**: Acquired TGF- $\beta$ 1 sensitivity and TGF- $\beta$ 1 expression in cell lines established from a single small cell lung cancer patient during clinical progression.  
Lung Cancer, 14: 63 - 73, 1996.
70. Kristensen CA, Jensen PB, **Poulsen HS**, Hansen HH: Small Cell Lung Cancer: Biological and therapeutic aspects.  
Critical Review in Oncology/ Hæmatol, 22: 27 - 60, 1996.
71. Pedersen AN, Højer-Hansen G, Brünner N, Clark GM, Larsen B, **Poulsen HS**, Danø K, Stephens RW: The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.  
J Immun Methods, 203: 55 - 65, 1997.
72. Krarup M, **Poulsen HS**, Spang-Thomsen M: Cellular Radiosensitivity of small-cell lung cancer cell lines.  
Int J Radiation Oncology Biol Phys, 38: 191 - 196, 1997.
73. Voldborg BR, Damstrup L, Spang-Thomsen M, **Poulsen HS**: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.  
Ann Oncol, 8: 1197 - 1206, 1997.
74. Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, **Poulsen HS**, Spang-Thomsen M, Nørgaard P: Loss of the retinoblastoma protein - related p130 protein in small cell lung carcinoma.  
Proc Natl Acad Sci, 94: 6933 - 6938, 1997.
75. Damstrup L, Voldborg BR, Spang-Thomsen M, Brunner N, H. **Poulsen HS**: In vitro invasion of small - cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.  
Br J Cancer, 78: 631 - 640, 1998.
76. Hougaard S, Krarup M, Nørgaard P, Damstrup L, Spang-Thomsen M, **Poulsen HS**: High value of the radiobiological parameter Dq correlates to expression of the transforming growth factor b type II receptor in a panel of small cell lung cancer cell lines.  
Lung Cancer, 20, 65 - 69, 1998.
77. Lassen U, Andersen P, Daugaard G, Holm S, Jensen M, Svarre C, **Poulsen HS**, Paulson OB: Metabolic and hemodynamic evaluation of brain metastases from small cell lung cancer with positron emission topography.  
Clin. Cancer Res., 501-3, 1998.

78. Lund EL, Spang-Thomsen M, **Poulsen HS**, Kristjansen PEG:  
Tumor angiogenesis - a new therapeutic target in gliomas.  
*Acta Neu Scand*, 97: 52 - 62, 1998.
79. Damstrup L, Kuwada SK, Dempsey PJ, Brown CL, Hawkey CJ, **Poulsen HS**,  
Wiley HS, Coffey RJ: Amphiregulin acts as an autocrine growth factor in two human  
polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis.  
*Br J Cancer*, 80: 1012 – 1019, 1999.
80. Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE,  
Oliff A, Coffey RJ, **Poulsen HS**, Moses HL: Treatment with farnesyl-protein transferase  
inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and  
TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.  
*Clin Cancer Res*, 5: 35 - 42, 1999.
81. Hougaard S, Nørgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M, **Poulsen HS**:  
Inactivation of the transforming growth factor  $\beta$  type II receptor in human small cell lung  
cancer cell lines.  
*Br J Cancer*, 79: 1005 - 1011, 1999.
82. Lassen U, Kristjansen PEG, Wagner Aa, Kosteljanetz M, **Poulsen HS**: Treatment of newly  
diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by  
radiotherapy. A phase II study.  
*J NeuroOncol*, 43: 161 – 166, 1999.
83. Schmiegelow M, Weber L, Lassen S, **Poulsen HS**, Hertz H, Müller J:  
Dosimetry and growth hormone deficiency following cranial irradiation of childhood brain tumors.  
*Med Pediatr Oncol*, 33: 564 – 571, 1999.
84. Law BK, Nørgaard P, Gnudi L, Kahn BB, **Poulsen HS**, Moses HL: Inhibition of DNA  
Synthesis by a Farnesyltransferase Inhibitor Involves Inhibition of the p70 (s6k) Pathway  
*J Biol Chem*, 19: 4743 - 4748, 1999.
85. Nørgaard P, Law BK, **Poulsen HS**, Moses HL: Farnesyltransferase inhibitor-induced  
regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates  
with inhibition of map kinase and p70s6 kinase phosphorylation.  
*Ann N Y Acad Sci*, 886: 265-8, 1999.
86. Frederiksen KS, Petri A, Abrahamsen N, Damstrup L, **Poulsen HS**: Gene therapy for Lung  
Cancer.  
*Lung Cancer*, 23: 191- 107, 1999.
87. Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, **Poulsen HS**: Gene  
delivery by an epidermal growth factor/ DNA polyplex to small cell lung cancer cell lines  
expressing low levels of epidermal growth factor receptor.  
*Cancer Gene Ther*, 7: 262 – 268, 2000.
88. Schmiegelow M, Lassen S, **Poulsen HS**, Feldt-Rasmussen U, Schmiegelow K., Hertz H,  
Müller JR: Biological Effective Dose-GH-Deficiency. Cranial radiotherapy of childhood brain  
tumors: Growth hormone deficiency and the relation to the biological effective dose of irradiation  
in a large population based study  
*Clin Endocrinol (Oxf)*;53(2): 191-7, 2000.
89. Schmiegelow M, Lassen S, **Poulsen HS**, Feldt-Rasmussen U, Schmiegelow K, Hertz H,  
Müller JR:  
Growth Hormone Response to a Growth Hormone Releasing Hormone Stimulation Test in a  
Population Based Study Following Irradiation of Childhood Brain Tumours.  
*Horm Res*, 54(2): 53-59, 2000.

90. Pedersen MW, Thykjær T, Ørntoft TF, Damstrup L, **Poulsen HS**: Profile of differentially expressed genes mediated by the Type III Epidermal Growth Factor Receptor mutation in small cell lung cancer cell line.  
Br J Cancer; 85( 8 ): 1211 - 1218, 2001.
91. Schmiegelow M, Lassen S, **Poulsen HS**, Schmiegelow K, Hertz H, Andersson AM, Skakkebæk NE, Müller J: Gonadal status in male survivors following childhood brain tumors.  
J Clin Endocrin Metab, 86: 2446 – 2452, 2001.
92. Wurtzen PA, Pedersen L, **Poulsen HS**, Claesson MH: Specific killing of P53 mutated tumor cell lines by cross-reactive human HLA-A2-restricted P53-specific CTL line.  
Int J Cancer, 93: 855-861, 2001.
93. Pedersen MW, Meltorn M, **Poulsen HS**: The Type III EGF receptor growth factor mutation. Ann Oncol, 12: 745 – 760, 2001.
94. Damstrup L, Pedersen MW, Bastholm L, Elling F, **Poulsen HS**: Epidermal Growth Factor Receptor Mutation Type III transfected into small cell lung cancer cell line is predominantly localized at the cell surface and enhance tumorigenicity.  
Int J Cancer, 97: 7 –14, 2002.
95. Mortensen S, Sørensen SB, **Poulsen HS**: Genterapi og cancer.  
Ugeskrif Læger, 164: 1785 – 1790, 2002.
96. Pedersen MW, **Poulsen HS**: Epidermal Growth Factor Receptor in Cancer Therapy.  
Science & Medicine, august: 206- 217, 2002.
97. Schmiegelow M, Feldt-Rasmussen U, Rasmussen ÅK, Hertz H, **Poulsen HS**, Müller J: Thyroid function in Childhood brain tumor. A population based study of Thyroid function after Radiotherapy and Chemotherapy for a Childhood brain tumor.  
J Clin Endocrinol Metab, 88(1): 136-40, 2003.
98. Hansen LRT, Lundin C, Helleday T, **Poulsen HS**, Petersen LN, Spang-Thomsen M: DNA repair rate and etoposide resistance in two tumor cell subpopulations derived from a single human small cell lung cancer.  
Lung Cancer, 40(2): 157-64, 2003.
99. Pedersen N, Mortensen S, Sørensen SB, Pedersen MW, Rieneck K, Bovin LF, **Poulsen HS**: Transcriptional gene expression profiling of small cell lung cancer cells.  
Cancer Res 63(8):1943-53. 2003.
100. Nielsen KL, Allen MR, Bloomfield SA, Andersen TL, Chen X, Xu T, **Poulsen HS**, Young MF, Heegaard M: Biglycan Deficiency interferes with ovariectomy-induced bone loss.  
J Bone Miner Res, 18(12): 2152-2158, 2003.
101. Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK, Lange M, **Poulsen HS**, Müller J: Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients treated with Cranial Radiotherapy for a Childhood Brain Tumor.  
J Clin Endocrinol Metab, 88(7): 3149-54, 2003.
102. Heydenreich AV, Westmeier R, Pedersen N, **Poulsen HS**, Kristensen HG: Preparation and purification of cationic nanospheres – effects on particle size, physical stability and cell toxicity.  
Int J Pharm, 254: 83-87, 2003.
103. Pedersen N, **Poulsen HS**: New drug modalities for treatment of lung cancer.  
Review Series Oncology, 2/2003: 2-6, 2003.

104. Pedersen MW, Tkach V, Pedersen N, Berezin V and **Poulsen HS**: Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases cell motility.  
Int J Cancer, 108: 643-653, 2004.
105. Christensen HC, Schüz J, Kosteljanetz M, **Poulsen HS**, Thomsen J, Johansen C: Cellular telephone use and risk for acoustic neurinoma.  
Am J Epidemiology, 159(3): 277-83, 2004.
106. Pedersen MW, Pedersen N, Damstrup L, Villingshøj M, Sønder SU, Rieneck K, Bovin LF, Spang-Thomsen M, **Poulsen HS**: Analysis of the epidermal growth factor receptor specific transcriptome: effect of expression level and an activating mutation.  
J Cell Biocem, 96(2): 412-427, 2005.
107. Poulsen TT, Pedersen N, Perin MS, Celia K, Hansen CK, **Poulsen HS**: Specific sensitivity of small cell lung cancer cell lines to the snake venom toxin taipoxin.  
Lung Cancer, 50(3): 329-337, 2005.
108. Christensen HC, Schüz J, Kosteljanetz M, **Poulsen HS**, Boice J, McLaughlin, Johansen C: Cellular telephone and risk for brain tumors. A population-based, incident case-control study.  
Neurology, 64(7): 1189-95, 2005.
109. Pedersen MW, Pedersen N, Ottesen LH, **Poulsen HS**: Differential response to gefinitib of cells expressing normal EGFR and the mutant EGFRvIII.  
Br J Cancer, 93: 915-923, 2005.
110. Poulsen TT, Pedersen N, **Poulsen HS**: Replacement and suicide gene therapy for targeted treatment of lung cancer.  
Clin Lung Cancer, 6: 227-236, 2005.
111. Pedersen N, Hansen SE, Heydenreich AV, Kristensen HG. and **Poulsen HS**: Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands.  
Eur J Pharm Biopharm, 62:155-162, 2006.
112. Pedersen N, Pedersen MW, Lan MS, Breslin MB, **Poulsen HS**: The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small cell lung cancer.  
Cancer Gene Ther, 13: 375-384, 2006.
113. Vestergaard J, Pedersen MW, Pedersen N, Ensinger C, Tümer Z, Tommerup N, **Poulsen HS**, Larsen LA: Hedgehog signaling in small-cell lung cancer: frequent *in vivo* but a rare event *in vitro*.  
Lung Cancer, 52:281-290, 2006.
114. Andersen PB, Blinkenberg M, Lassen U, Kosteljanetz M, Wagner A, **Poulsen HS**, Sørensen PS, Paulson OB: A prospective PET study of patients with glioblastoma multiforme.  
Acta Neurol Scand, 113(6): 412-8, 2006.
115. Pedersen MW, **Poulsen HS**: Mutationer i EGF receptoren: struktur og tumorbiologisk relevans.  
Ugeskr Læger, 168:2354-2361, 2006.
116. **Poulsen HS**: Gliomer hos voksne: Primær ikke kirurgisk behandling.  
Ugeskr Læger, 168: 4082-5, 2006.
117. Spindler K-LG, Olsen DA, Nielsen JN, Brandslund I, **Poulsen HS**, Villingshøj M, Jakobsen A: Lack of the Type III Epidermal Growth Factor Receptor Mutation in Colorectal Cancer.  
Anticancer Res, 26 (6C): 4889-93, 2006.
118. Pedersen N, Poulsen TT, **Poulsen HS**: Cre/*loxP* recombination vectors for promoter studies.  
Electron J Biotechol, 10:315-321, 2007.

119. Larsen AB, Pedersen MW, Stockhausen M, Grandal MV, van Deurs B, **Poulsen HS**: Activation of the EGFR target gene EphA2 inhibits EGF-induced cancer cell motility. *Molecular Cancer Research*, 5(3): 283-293, 2007.
120. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, **Poulsen HS**: EGFRvIII escapes downregulation due to impaired internalization and sorting to lysosomes. *Carcinogenesis*, 28(7): 1408-17, 2007.
121. Zandi R, Larsen AB, Andersen P, Stockhausen MT, **Poulsen HS**: Mechanisms for oncogenic activation of the epidermal growth factor receptor. *Cellular Signalling*, 19 (10) 2013-23, 2007.
122. Andersen P, Pedersen MW, Woetmann A, Stockhausen MT, Ødum N, **Poulsen HS**: EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. *Int. J. Cancer*, Jan 15; 122(2): 342-9, 2008.
123. Poulsen TT, Pedersen N, **Poulsen HS**: A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. *Cancer Gene Therapy* 15: 563-575, 2008.
124. Hansen CL, Hansen PR, Pedersen N, **Poulsen HS**, Gillings N, Kjær A: Identification of amino acid residues in PEPHC1 important for binding to the tumor-specific receptor EGFRvIII. *Chem Biol Drug Des.* 72(4): 273-82, 2008.
125. Poulsen TT, Naizhen X, **Poulsen HS**, Linnoila IR: Acute damage by naphthalene triggers expression of the neuroendocrine marker PGP9.5 in airway epithelial cells. *Toxicol Lett* 181: 67-74, 2008.
126. **Poulsen HS**, Grunnet K, Sørensen M, Olsen P, Hasselbalch B, Kosteljanetz M, Lassen U: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. *Acta Oncologica.* 48(1): 52-8, 2009.
127. Andersen P, Villingshøj M, **Poulsen HS**, Stockhausen MT: Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells. *Cancer Invest* 27 (2): 178-83, 2009.
128. Denholt CL, Hansen PR, Pedersen N, **Poulsen HS**, Gillings N, Kjær A: Identification of novel receptor binding ligands for EGFRvIII using a mixture-based synthetic combinatorial library. *Biopolymers.* 91(3): 201-206, 2009.
129. Christensen CL, Zandi R, Gjetting T, Cramer F, **Poulsen HS**: Specifically targeted gene therapy for small cell lung cancer. *Expert Review of Anticancer therapy.* 9(4): 437-52, 2009.
130. Stockhausen MT, Kristoffersen K, **Poulsen HS**: The Functional role of Notch signaling in human gliomas. *Neuro Oncol.* 2010 Feb; 12(2): 199-211
131. Sørensen M, Gaziel TB, Hasselbalch B, **Poulsen HS**, Lassen U: Severe skin lesions in patients with glioblastoma multiforme treated with a combination of cetuximab, bevacizumab and irinotecan. *European Journal of Clinical & Medical Oncology* 1(2): 1-3, 2009

132. Larsen AB, Stockhausen M, and **Poulsen HS**: Cell adhesion and EGFR activation regulate EphA2 expression in cancer. *Cellular Signalling* 22:636-644, 2010
133. Kosteljanetz M, **Poulsen HS**: Kemoterapi imprægnerede wafers i behandlingen af maligne gliomer i hjernen. En gennemgang af et Cochrane Review. *Ugeskrift for Læger*, Jan 18; 172(3): 214-217,2010
134. Madsen K, **Poulsen HS**: Needs for support in everyday life for next of kin to brain tumor patients: a systematic literature review. *European Journal of Cancer Care*. April 2010
135. Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, **Poulsen HS**: Targeted cytosine deaminase-uracil phosphoribosyl transferase induces SCLC specific cytotoxicity and tumor growth delay. *Clin Cancer Res* 16(8) April 15,2010
136. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, **Poulsen HS**: Cetuximab, Bevacizumab and Irinotecan for Patients with Primary Glioblastoma and Progression after Radiation Therapy and Temozolomide: A Phase II trial. *Neuro Oncol*. 2010 May; 12(5): 508-16
137. Hasselbalch B, Lassen U, Poulsen HS, Stockhausen MT: Cetuximab is insufficient in inhibiting cell growth due to persistent EGFR downstream signalling. *Cancer Investigation* 2010 (in press)
138. Gjetting T, Arildsen NS, Christensen CL, Poulsen TT, Roth JA, Handlos VN, **Poulsen HS**: In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection. *Int. J. Nanomedicine* 2010: 5 371-383
139. Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Laursen H, Katita O, Kolar Z, **Poulsen HS**, Broholm H, Lukas J, Bartek J: Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signaling in human gliomas. *Oncogene* 2010: Jun 2010
140. Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, **Poulsen HS**, Stockhausen MT, Lassen U: Prospective evaluation of angiogenic, hypoxic and EGFR related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. *APMIS* 2010 (in press)

#### Artikler submitted

1. Denholt CL, Kuhnast B, Hinnen F, Pedersen N, **Poulsen HS**, Dollé F, Hansen PR, Kjær A: Fluorine-18 labelling studies of PEPHC1, a peptide specific towards EGFRvIII, and a number of truncated analogues. Submitted 2009.
2. Denholt CL, Binderup T, Stockhausen MT, **Poulsen HS**, Spang-Thomsen M, Hansen PR, Gillings N, Kjær A: In vivo evaluation of 18-F FBA-FALGEA-NH2 as a Pet tracer for EGFRvIII imaging. Submitted 2009.
3. Zandi R, Selivanova G, Christensen CL, Willumsen BM, **Poulsen HS**: "PRIMA-1Met induces apoptosis in Small Cell Lung Cancer expressing mutant p53". Submitted 2009.

## Artikler uden peer review

1. **Poulsen HS**, Ozzello L, King WJ, Greene GL:  
Immunocytochemistry of oestrogen receptors in human breast cancer.  
Reviews Endocrine-Rel Cancer 19: 21-26, 1986.
2. Brünner N, Spang-Thomsen M, **Poulsen HS**, Vindeløv L, Engelholm SA:  
Effect of tamoxifen on growth and cell kinetics of two human breast carcinomas grown in nude mice.  
Reviews Endocrine-Rel Cancer 19: 125-130, 1986.
3. Ørntoft T, Bendtsen L, **Poulsen HS**, Petersen SE, Wolf H, Pedersen S, Bolund L:  
Dual parameter flow cytometric measurement of DNA-content and lectin binding in human bladder tumors.  
In: Lectins, vol. V. TC Bøg-Hansen, E. van Driessche (eds). Berlin - New York. Walter de Gruyter & Co. pp. 545-550, 1986.
4. Brünner N, Spang-Thomsen M, **Poulsen HS**, Vindeløv L, Engelholm SA:  
Characterization of the T60 human breast carcinoma grown in nude mice: special reference to endocrine therapy studies.  
In: Immune-deficient Animals in Biochemical Research. Rygaard J, Spang-Thomsen M, Brünner N Græm N.  
Basel: Karger Publishing, pp. 234-241, 1987.
5. **Poulsen HS**, Rytter L, Brünner N, Ørntoft T, Andersen J, Spang-Thomsen M:  
Steroid receptor profile in human breast cancer grown in nude mice.  
In: Immune-deficient Animals in Biochemical Research. J. Rygaard, M. Spang-Thomsen, N. Brünner, N. Græm (eds). Basel, Karger Publishing, pp. 255-259, 1987.
6. Brünner N, **Poulsen HS**, Clarke R, Spang-Thomsen M: Effect of oophorectomy on estrogen and progesterone receptor concentrations in an ovarian-dependent and ovarian independent human breast cancer grown in nude mice.  
In: Wu B-q, Zheng J (eds): Immune-deficient Animals in Experimental Medicine. 6 th. Int. Workshop on Immune-deficient animals, Karger, Basel, pp: 196-201, 1989.
7. Damstrup L, Andersen J, Kufe DW, Hayes DF, **Poulsen HS**: Estrogen-regulated proteins in human breast cancer: Clinical value in advanced breast cancer and correlation with estrogen receptor.  
In: Recent advances in cellular and molecular biology, edited by Wegman,R.J. and Wegman,M.A., Leuven, Belgium: Peeters Press, p. 243-251, 1992.
8. Krarup M, **Poulsen HS**, Spang-Thomsen M: Expression of cell cycle regulating mRNA in small cell lung cancer xenografts.  
Folia Microbiologica 43: 501 - 503,1998.
9. **Poulsen HS**, Ulrichsen H. Kommentar: Når læger laver medicin.  
Ugeskrift Læger 40: 5545 – 5546, 2001.

## Bogkapitler

1. **Poulsen HS**: In vitro observations in relation to response, Chp.7.  
In: Endocrine Management of Cancer 1: Biological bases. B. Stoll (ed). Basel: Karger Publishing 1988, pp. 72-83.
  2. Olsen I, **Poulsen HS**, Kosteljanetz M: Værd at vide om hjernesvulster.  
Finsenscenter, Rigshospitalet 1996, 1- 36.
  3. Geisling PQ, **Poulsen HS**, Kosteljanetz M: Hjernesvulster.  
Kræftens Bekæmpelse, 1996, 1- 36.
  4. Hougaard S, Nørgaard P, **Poulsen HS**: TGF $\beta$  and lung cancer.  
In: J.R. Benson: TGF- beta and Cancer. Landes Bioscience Publishers 1997.
  5. Frederiksen KS, Petri A, Abrahamsen N, **Poulsen HS**: Gene therapy of Lung Cancer.  
In: F. Hirsch: Lung Cancer, 1999.
  6. Poulsen TT, Pappot H, **Poulsen HS**. Molecular Biology in Lung Cancer. IASLC Textbook on Lung Cancer, 2nd edition, edited by Hansen HH, Informa Healthcare, 2008.
  7. Hasselbalch B, Lassen U, **Poulsen HS**. Patients with Recurrent High-Grade Glioma: Therapy with Combination of Bevacizumab and Irinotecan. In "Tumors of the central nervous system" edited by M.A. Hayat. In press
- 

## Patenter

1. Co- inventor of: Targeted gene therapy in small cell lung cancer. 2000-03-17  
**(Agent: Ploughmann, Vingtoft & Partners)**.
2. Co- inventor af : Oncology Drug Innovation. Receptorer og promotorer til genterapi. 2001-06-25  
*Patent PA 2001 00992 og 2002 (Agent: Høiberg Aps)* Publication date 3. January 2003, Patent number WO03000928.
3. Co-inventor af: Insulinoma Associated-1 promoter-specific therapy of neuroendocrine tumors. 2005  
**(Agent: Taylor, Porter, Brooks & Phillips L.L.P)**.

## Internationale reviews

1. Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N,  
**Poulsen HS**, Stahel R, Takahashi T, Twentyman P.  
Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13 - 17, 1996, Ermatingen, Switzerland.  
Commentary.  
Ann Oncology 8: 27 - 36, 1997.
2. Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N,  
**Poulsen HS**, Stahel R, Takahashi T, Twentyman P.  
Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13 - 17, 1996, Ermatingen, Switzerland.  
Commentary.  
Lung Cancer 16: 239 - 257, 1997.

